

NORTH CAROLINA BOARD OF PHARMACY

In Re:)
)
Med Care Choice Pharmacy) ORDER SUMMARY
(Permit No. 11994)) SUSPENDING PHARMACY
) PERMIT
)

Pursuant to G.S. § 150B-3(c) and 21 N.C.A.C. 46.2006(b), the North Carolina Board of Pharmacy (“Board”), vis Members Gene Minton, Robert Graves, Stan Haywood, Keith Vance, Stan Haywood, and Andy Bowman, find that the protection of the public health, safety and welfare requires emergency action. Accordingly, the Board hereby Summarily Suspends Permit No. 11994 issued to Med Care Choice Pharmacy (“Respondent Pharmacy”), effective upon service of this Order. Respondent Pharmacy shall immediately cease any practice of pharmacy in North Carolina pending issuance by the Board of a Final Agency Decision.

Respondent Pharmacy may request a hearing on the charges against you by submitting a written request within sixty (60) days of service of this order, pursuant to 21 N.C.A.C. 46. 2004. Within sixty (60) days of receipt of your written request, the Board will issue a notice of hearing with respect to whether the summary suspension should be continued. That notice will advise Respondent Pharmacy of the date and time of the hearing, which will be set within the discretion of the Board. In the event that Respondent Pharmacy requests a hearing, this summary suspension remains in effect until the issuance of a further decision by the Board.

If Respondent Pharmacy does not request a hearing as set forth above, the Respondent Pharmacy waives the right to contest the Board’s decision and the summary suspension imposed upon the permit by this order. However, the Respondent Pharmacy retains the right to file a written petition for reinstatement of permit at any time following this order. The Board will set a

hearing at a time and place within its discretion and will rule on the petition for reinstatement, in its discretion, under its duty to consider the public health, safety and welfare.

By Order of the Board, this 16th day of May, 2017.

NORTH CAROLINA BOARD OF PHARMACY



Jack W. Campbell, IV
Executive Director